Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQB:BABYF) – Company Profile
Quote Close Prices Trades Chart News Company Analyst Corp. Events Share Info Key Ratios Filings Earnings

Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQB:BABYF) Company Profile

Founded in British Columbia, but with a head office in Tel Aviv, Israel, Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQB:BABYF) is a food and nutrition company focused on research, development, manufacturing, marketing, sale and/or license of plant-based food and nutrition products to the infant, toddler, children, and adult markets.

The company’s 100% plant-based non-soy alternative to traditional milk-based baby formula is the first of its kind on the market. It’s free of GMOs, pesticides, hormones, antibiotics, gluten, and phytoestrogens, and has no externally added macro-nutrients.

Made from almonds and buckwheat, Else Nutrition’s formula is a healthier and more natural option for toddlers (12-36 months) as a real alternative to dairy-based baby formulas. It meets the nutritional golden standard of breast milk and is the best solution for lactose intolerance and other sensitivities that keep babies from experiencing the benefit of existing products.

In May 2017, it received the “Best Health and Diet Solutions” award in the Global Food Innovation Summit in Milan. The product has a completely sustainable ecological footprint and has been medically endorsed by leading pediatric experts. 

And if all that wasn’t enough, it tastes great!


How Else Nutrition Can Disrupt a $90+ Billion Market

According to a report from Hexa Research, the global market for infant formula is expected to reach 90 billion USD by 2025. It’s currently growing at a CAGR of 9.35%, driven in large part by the introduction of milk formulas with additional nutrition.

What’s most interesting about this market value, though, is that Else Nutrition has the only no-dairy, no-soy, 100% plant-based formula on the market. 

The vast majority of infant formulas are milk-based, despite the fact that cow’s milk is the number one allergen for children aged five or younger. Milk allergies currently affect half of American food-allergic children who are less than one year old. Nearly all of the non-dairy alternatives are soy-based, but approximately 40% percent of children allergic to cow’s milk are also allergic to soy milk.

This means that there are entire sectors of the market that only Else Nutrition can reach. 

As the global organic baby food market is projected to grow from $5.95 billion in 2018 to $11 billion by 2024—with a CAGR of 11% between 2019 and 2024—Else Nutrition is in an incredibly envious position compared to its peers. 



Patent-Protected, Cash-Rich, and Ready for Retail

Else Nutrition is finalizing research and development for its infant formula, and both its toddler and children formulas are market-ready. The company enjoys a very strong IP portfolio that is valid through 2034.

On top of that, Else has been granted patents in at least 20 countries to date, including the United States, Australia, Japan, Ukraine, Russia, South Africa, and New Zealand. It also has an additional 50+ patents pending.

The company is already earning revenue from the sale of its vegan baby snacks and other accessories in Israel. These products generated $900,000 for Else last year, and when they are launched in America in 2020, the company expects them to generate $350,000 in the first year and double that in the second year.

Else Nutrition also expects sales of toddler formula and kids’ nutritional drinks to begin in the spring of 2020 in the US. The formula will be available in powder and liquid forms.

In July, the company raised $7.5 million CAD in financing from Canaccord Genuity Inc. It has a current market cap of $33.57 million CAD.


Meet The Else Nutrition Management Team

Hamutal Yitzhak, Co-Founder & CEO – Hamutal is the
the former head of infant nutrition at Abbott Labs Israel and is a
founding member and partner of Heart Baby Snack Co.

 

Uriel Kesler, Co-Founder & COO – Uriel is a former GM PL
infant formula at Promedico Healthcare Group. Like Hamutal,
he is a founding member and partner in Heart Baby Snack Co.

 

Michael Azar, Co-Founder & CTO – Michael is an infant
nutrition production expert. He was formerly the CEO & Chief
Food Technologist at Materna, which has been acquired by Nestle. 



Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2)The Article was issued on behalf of a third party, Else Nutrition Holdings Inc. Market Jar Media Inc. has or expects to receive thirty-nine thousand, four hundred and sixty Canadian dollars from Else Nutrition Holdings Inc.’s agency of record Native Ads Inc. for 26 days (20 business days).

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on Microsmallcap.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.